According to filings with the U.S. Securities and Exchange Commission, Cartesian Therapeutics is raising up to $130,023,000.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Blaine Davis played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cartesian Therapeutics
In November 2023, Selecta Biosciences Inc. (NASDAQ: SELB) merged with Cartesian Therapeutics to create a publicly traded company pioneering RNA cell therapy to treat autoimmune disease. The combined company will focus on advancing Cartesians wholly owned pipeline, including Descartes-08, Cartesians clinical-stage lead product candidate being evaluated in patients with myasthenia gravis and other autoimmune diseases.

To learn more about Cartesian Therapeutics, visit http://www.cartesiantherapeutics.com/
Cartesian Therapeutics Linkedin Page: https://www.linkedin.com/company/cartesian-therapeutics/

Contact:
Blaine Davis, Chief Financial Officer
617-923-1400

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.